Hello wim58-ga,
Thank you for asking for me by name. The project turned out to be an
interesting plunge into the world of biotech mergers and acquisitions.
It?s amazing how many of the companies on your list are no longer in
business under the same name. Some of them have gone through multiple
incarnations. LION bioscience AG seems to be in serious acquisition
mode and has gobbled up several of the companies on yur list.
I took your list and gave you the official version of the company name
and the web site URL. If the company was no longer in business, I
followed the trail and included the press releases or other
announcements which led me to the newest information.
Best wishes for your project.
~ czh ~
Genomica Corporation
http://www.exelixis.com/index.asp?secPage=arcrelease&rel=61
November 19, 2001
Exelixis, Inc. (Nasdaq: EXEL) and Genomica Corporation (Nasdaq: GNOM)
have signed a definitive agreement whereby Exelixis will acquire
Genomica in a stock-for-stock transaction valued at $110 million.
http://www.exelixis.com/index.asp
Exelixis, Inc.
Exelixis is a genomics-based drug discovery company focused on the
discovery and development of potential new drug therapies,
specifically for cancer and other proliferative diseases. Our primary
mission is to develop proprietary human therapeutics by leveraging our
integrated gene-to-drug platform to increase the speed, efficiency and
quality of pharmaceutical product discovery and development.
-------------------------------------------------
ID Business Solutions, Ltd (IDBS)
http://www.id-bs.com/
IDBS Worldwide
IDBS is a worldwide provider of advanced software solutions for the
pharmaceutical, biotechnology, agrochemical and animal health
industries. Robust, rapidly deployable applications such as our
flagship ActivityBase suite help streamline decision-making and
accelerate the discovery process by enabling scientists throughout the
extended organisation to share knowledge and process information
faster and more accurately.
-------------------------------------------------
Incyte Genomics, Inc
http://www.incyte.com/
Incyte Corporation
Incyte is a drug discovery company applying its expertise in genomics,
medicinal chemistry and molecular, cellular and in vivo biology to the
discovery and development of novel small molecule and protein
therapeutics. ? We have three active discovery programs focused on the
identification of novel small molecule drugs for cancer and
inflammation. Incyte also has strategic alliances with Lexicon
Genetics and Medarex focused on the discovery and development of
therapeutic proteins and antibodies to treat inflammatory diseases and
cancer.
-------------------------------------------------
InforMax, Inc
http://www.informaxinc.com/
http://www.informaxinc.com/content.cfm?pageid=1
InforMax
InforMax delivers a family of highly integrated, graphically rich
software solutions to increase your research productivity and enhance
your experimental strategies. ? More than 32,000 life scientists
worldwide have adopted the Vector Family of Software Products to ease
and enhance mining, analysis, presentation, and storage of biological
data.
http://www.informaxinc.com/content.cfm?pageid=5
InforMax is a global leader delivering innovative informatics software
and services that increase the effectiveness and productivity of life
scientist researchers. Since being acquired by Invitrogen Corporation
in late 2002, InforMax has been increasing the value we deliver to
customers by developing an expanded portfolio of analytical software
tools that connect dry lab experimental planning, design, and data
analysis with conventional wet lab techniques in molecular biology.
This powerful combination of software tools and reagents provides
researchers with the most integrated and versatile platform on the
market to effectively manage and speed drug discovery research.
http://www.invitrogen.com/
Invitrogen Corporation
Invitrogen Corporation (Nasdaq:IVGN) provides products and services
that support academic and government research institutions, and
pharmaceutical and biotech companies worldwide in their efforts to
improve the human condition. The company provides essential life
science technologies for disease research, drug discovery, and
commercial bio-production. Invitrogen's own research and development
efforts are focused on breakthrough innovation in all major areas of
biological discovery including functional genomics, proteomics,
bio-informatics and cell biology -- placing Invitrogen's products in
nearly every major laboratory in the world.
-------------------------------------------------
InnaPhase Corp
http://www.innaphase.com/
InnaPhase Corporation
InnaPhase Corporation is the leading supplier of LIMS solutions
dedicated to the pharmaceutical industry. The 21 CFR Part 11 compliant
Pharma LIMS? Suite includes: Newton? LIMS for analytical development,
quality control and stability testing; Watson? LIMS for
DMPK/Bioanalytical studies in drug development; and Galileo? LIMS for
In Vitro testing.
-------------------------------------------------
Inpharmatica, Ltd
http://www.inpharmatica.co.uk/
Inpharmatica
Inpharmatica is a leading informatics-driven drug discovery company.
It applies information from its two platform informatics technologies,
PharmaCarta? and Biopendium?, integrated with its Discovery Biology
facility, to the discovery of novel, druggable targets and drug
compounds themselves.
-------------------------------------------------
Leadscope, Inc
http://www.leadscope.com/
Leadscope Inc.
Leadscope develops and markets a chemoinformatics application that
provides seamless access to pharmaceutical research data. It
incorporates chemically based data mining, visualization and advanced
informatics techniques (prediction tools, scaffold generators, etc.).
The platform, coupled with our Toxicity and Known Drugs databases,
provides a comprehensive in silico drug discovery solution.
-------------------------------------------------
Lhasa, Ltd
http://www.chem.leeds.ac.uk/luk/
LHASA Limited
LHASA Limited is an independent, not-for-profit company established in
1983 with offices located in the Department of Chemistry at the
University of Leeds. Organisations who use our software become
members of the company and thereby control it. LHASA Limited is an
international company with members in Europe, North America and Japan.
LHASA Limited's aim is to develop and promote the use of high quality
expert computer systems in the chemical and biomolecular sciences for
the benefit of the members of LHASA Limited and the wider scientific
community.
-------------------------------------------------
LION Bioscience AG
http://www.lionbioscience.com/
LION bioscience AG
LION bioscience is dedicated to improving the research productivity of
the life science industry. ? LION?s core product is the integration
platform LION DiscoveryCenter?. The first version of LION
DiscoveryCenter? was unveiled in January 2003. This platform
integrates both biological and chemical data. An integral part of LION
DiscoveryCenter? is SRS, LION?s market-leading integration platform
for biological data. The system architecture is open, scalable and
modular ? in other words it is suited to a growing number of users and
can meet increasing technological and content requirements. Its open
environment allows customers to continue using their internally
developed or licensed applications.
-------------------------------------------------
MDL Information Systems, Inc
http://www.mdli.com/
MDL Information Systems, Inc.
MDL is the pioneering leader in discovery informatics. Over 1,000 life
science companies supercharge their discovery engines with MDL
software solutions to generate fresh ideas and make breakthrough
discoveries. By synchronizing and streamlining the sharing and
management of vital information and knowledge, we enable scientists to
work more efficiently.
MDL is a wholly owned subsidiary of Elsevier, Inc. and a part of
Elsevier Life Sciences division.
http://www.mdli.com/company/about/about_elsevier.jsp
Elsevier Life Sciences
Elsevier Life Sciences division combines Elsevier?s 400 chemistry and
life science journals and related products (including Cell, Neuron,
Journal of Molecular Biology, Tetrahedron Letters, ScienceDirect, and
BioMedNet) with MDL?s extensive informatics, database, workflow, and
decision support solutions. This unique combination enables Elsevier
Life Sciences to bring unparalleled solutions to researchers,
significantly advancing the efficient, cost-effective development of
new medicines.
Elsevier, Inc.
http://www.elsevier.com
Elsevier, Inc.
Elsevier, Inc. is a leading publisher of scientific, technical, and
medical information products and services. Working in partnership with
the global science and health communities, the company publishes more
than 1,800 journals and 2,200 new books per year, in addition to
offering a suite of innovative electronic products, bibliographic
databases, online reference works, and subject-specific portals.
http://www.reedelsevier.com
Reed Elsevier Group plc
Elsevier, Inc. is a part of Reed Elsevier Group plc, a world-leading
publisher and information provider. Reed Elsevier is owned equally by
Reed Elsevier PLC and Reed Elsevier NV, which are listed on the
London, Amsterdam, and New York Stock exchanges under the following
ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Reed Elsevier has a market capitalization of over US $15 billion and
employs 36,000 people, including approximately 22,000 in North
America. Operating in the scientific, legal, educational and
business-to-business sectors, it provides high value and flexible
information solutions to professional end users, with increasing
emphasis on internet delivery.
-------------------------------------------------
Molecular Mining Corp
http://www.molecularmining.com/
Link automatically transfers to preditivepatterns.com
http://biotech.deep13.com/Graveyard/MolecularMining.html
Updated: 8/17/2003
Molecular Mining Corp. Makers of gene expression analysis software.
Molecular Mining was founded in 1997. The technology and software may
or may not live on, but the company does not. They went out of
business in March 2003
http://biotechnology.press-world.com/v/48185.html
06/04/2003
Predictive Patterns Licenses GeneLinker Products and Technology
Predictive Patterns Software Inc. is pleased to announce that we have
licensed the rights to sell, support and develop new versions of the
award-winning GeneLinker(TM) product-line from Parteq Innovations, the
Queen's University's technology transfer company.
Predictive Patterns is a new company founded by Dr. Tom Radcliffe
(President) and Mark Chatterley (Vice-President). They are the
Director and Manager of Software Development from the former Molecular
Mining Corporation, which developed the original GeneLinker products
and ceased operations in March 2003.
http://www.predictivepatterns.com/
Predictive Patterns Software
Predictive Patterns Software Inc. was founded by the former Director
and Manager of Software Development from the former Molecular Mining
Corporation on May 5, 2003. We have licensed the right to sell,
support and continue to develop the GeneLinker line of software
products following Molecular Mining's closing on March 6, 2003.
-------------------------------------------------
MULTICASE, Inc
http://www.multicase.com/
Multicase Inc
We develop and license computer programs designed to help a user to
assess the potential pharmacological activity, toxicity and metabolic
transformation of new chemicals. MultiCASE Inc. (formerly BIOSOFT
Inc.) is a Software company started in Cleveland Ohio in 1996. The
principals are Gilles Klopman, the Charles F. Mabery Professor of
Chemistry at Case Western Reserve University (CWRU) and CWRU. Its
business is to develop and license programs for use by chemical and
pharmaceutical companies to design new useful molecules and to
evaluate their impact on the environment at an early stage of
development.
-------------------------------------------------
Myriad Genetics
http://www.myriad.com/index.htm
Myriad Genetics Inc.
Myriad Genetics, Inc. is a biopharmaceutical company focused on the
development of therapeutic and diagnostic products. The Company's
emphasis on product development is demonstrated in its major business
components:
-- Therapeutic product development in important disease areas
-- Identification of disease-causing genes, as potential drug targets
-- Disease pathway discovery to isolate additional drug targets for development
-- Predictive medicine testing for inherited risk of disease
-------------------------------------------------
Nanodesign
http://www.nanodesign.com/
The page cannot be displayed
http://informagen.com/Resource_Informagen/Full/5/12315.php
Nanodesign, Inc.
Guelph Ontario Canada
Founded: 1997
Status: acquired in 2000 by SignalGene
http://www.signalgene.com/
Signalgene inc
The page cannot be displayed
http://news.tradingcharts.com/futures/1/0/50848501.html
SignalGene Shareholders Approve Resolutions Supporting Transformation
of Company to Oil and Gas Enterprise
MONTREAL, CANADA, Nov 6, 2003 (CCNMatthews via COMTEX) -- SignalGene
Inc. (TSX: SGI) today announced that, at a special general meeting of
shareholders held this morning in Montreal, the Company's shareholders
approved four resolutions, including one to issue 100,732,500 Common
Shares and 21,192,500 Preferred Shares, Series 1, supporting the
Company's intention to transform itself to an oil and gas enterprise.
More than 93% of shareholders voted in favour of each of the
resolutions.
-------------------------------------------------
NetGenics, Inc
http://www.netgenics.com
Automatically transfers to http://www.lionbioscience.com/
http://www.lionbioscience.com/press/release/2002/e9068/index_eng.html
HEIDELBERG, Germany, and CLEVELAND, Ohio, USA, January 15, 2002 ? LION
bioscience AG (Neuer Markt: LIO, WKN 504 350, Nasdaq: LEON) today
announced that it has agreed to acquire NetGenics, Inc., a privately
held company that builds integrated informatics solutions, in exchange
for approximately 1.12 million LION shares coming from authorized
capital.
http://www.lionbioscience.com/press/release/2002/e9060/index_eng.html
HEIDELBERG, Germany, January 31, 2002 ? LION bioscience AG (Neuer
Markt: LIO, WKN: 504 350; Nasdaq: LEON) announced today that it has
completed the acquisition of all of the equity of NetGenics Inc. in
exchange for LION American Depository Shares (ADS) effective January
30, 2002.
-------------------------------------------------
Neurogen Corp
http://www.neurogen.com/
Neurogen Corporation
Neurogen is a leading small molecule drug discovery and development
company targeting new drug candidates to improve the lives of patients
suffering from neurological, inflammatory, pain and metabolic
disorders. ? Neurogen's Accelerated Intelligent Drug Discovery(AIDD)
system, its expertise in cellular functional assays, and its depth in
medicinal chemistry are key discriminators in the Compay's ability to
rapidly and cost-effectively identify new drug candidates.
-------------------------------------------------
NovaScreen Biosciences
http://www.novascreen.com/
Novascreen Biosciences Corporation
NOVASCREEN Biosciences Corporation provides innovative services and
database products to improve the productivity, accelerate the pace,
and reduce the cost of pharmaceutical research and development. ? Our
NOVASCREEN Screening Services business provides comprehensive,
convenient and cost-effective drug discovery and development services
based on our screening assay platform to major pharmaceutical and
biotechnology companies worldwide. Our Pharmacoinformatics Database
business, which is built on the NOVASCREEN Services Screening assay
platform, is creating a series of content databases and software tools
that will provide a comprehensive and predictive map of the molecular
recognition patterns and functional activity relationships between
drug targets and drug-like chemical compounds.
-------------------------------------------------
Oxford GlycoSciences plc
http://www.ogs.com/
Oxford GlycoSciences Plc
Oxford GlycoSciences Plc (LSE: OGS; NASDAQ: OGSI) is a
biopharmaceutical company applying proteomics technologies and
glycobiology to the discovery, development and commercialisation of
novel therapeutic products.
Our own drug discovery efforts focus on three main therapeutic areas:
cancer, anti-infective and glycolipid storage disorders. In July 2002,
OGS' lead compound, Zavesca? (miglustat) received a positive opinion
from the Committee for Proprietary Medicinal Products. In June 2002 a
'non approvable'
letter was received from the FDA.
-------------------------------------------------
Oxford Molecular Group plc
http://www.accelrys.com/about/oxmol.html
Oxford Molecular is now Accelrys
Oxford Molecular was incorporated into Accelrys Inc. on June 1, 2001.
http://www.accelrys.com/
Accelrys Inc.
Accelrys is the leading provider of simulation and informatics
software and services to R&D organizations in the pharmaceutical,
biotechnology, and chemicals industries. ? Accelrys delivers software
and services based on its industry-leading expertise in informatics
and computation for the biological, chemical, and materials sciences.
The result is the accelerated design, discovery, and development of
pharmaceuticals, chemicals, and materials.
Accelrys is a wholly owned subsidiary of Pharmacopeia Inc.
Pharmacopeia, Inc
http://www.pharmacopeia.com/
Pharmacopeia
Pharmacopeia provides experimental, computational, and informatics
products and services to accelerate and improve the design, discovery
and development of new pharmaceuticals and chemicals. ? Pharmacopeia
is a leader in enabling technology-based products and services that
improve and accelerate drug discovery and chemical development.
Pharmacopeia is not associated with the US Pharmacopeia. They are
located at http://www.usp.org
-------------------------------------------------
PharmQuest Corp
http://www.pharmquest.com/default.html
PharmQuest Corporation
PharmQuest collaborates with the Pharmaceutical & Biotechnology
Industries to provide software that significantly improves efficiency
and compliance in the preclinical and product development process.
PharmQuest develops and markets a suite of innovative products and
solutions to enable pharma/biotech companies to maximize their R&D
investment and facilitate electronic submissions to regulatory
agencies. PharmQuest's products are developed using standards-based,
open-architecture software modules that can be fully integrated to
enhance project, information and knowledge management company-wide.
PharmQuest's solutions include ToxQuest and Product Devleopment
Management System (PDMS).
-------------------------------------------------
Pharsight Corp
http://www.pharsight.com/
Pharsight Corporation
Pharsight Corporation develops and markets integrated products and
services that enable pharmaceutical and biotechnology companies to
achieve significant and enduring improvements in the development and
use of therapeutic products. The company?s goal is to help customers
reduce the time, cost and risk of drug development, as well as
optimize the post-approval marketing and use of pharmaceutical
products.
Our management, consulting and technical staff have a broad range of
expertise and experience in key drug development disciplines including
clinical pharmacology, drug and disease modeling, human genetics,
biostatistics, decision science, clinical development and information
technology.
-------------------------------------------------
Physiome Sciences, Inc
http://www.physiome.com/
Following Physiome's acquisition of and merger with Predix
Pharmaceuticals, Ltd., details of the merged company can be found at
www.predixpharm.com.
http://www.physiome.com/
http://www.predixpharm.com
Predix Pharmaceuticals, Inc. is a drug discovery and development
company offering unique value for both today's biotech investor and
tomorrow's medical patient. By tightly integrating our proprietary 3D
computational chemistry technologies with traditional medicinal
chemistry, we have created a drug discovery platform that dramatically
accelerates the generation of new drugs associated with G-protein
coupled receptors (GPCRs) and ion channels.
http://www.predixpharm.com/press_releases/merger.htm
Physiome Sciences and Predix Pharmaceuticals Announce Merger
Woburn, MA and Princeton, NJ, August 12, 2003 ? Predix
Pharmaceuticals, Inc., and Physiome Sciences, Inc., two private
companies specializing in computational expertise and biological
modeling to increase the speed and efficiency of drug development,
announced today that they have signed an agreement in which Physiome
acquired Predix Pharmaceuticals in exchange for 30% of the combined
equity of the two companies. The combined company, initially named
Predix Pharmaceuticals Holdings, Inc., will be known as Predix
Pharmaceuticals, Inc., and will be headquartered in Woburn, MA with
computational development offices in Ramat Gan, Israel.
-------------------------------------------------
Pitch (Sweden)
?????
-------------------------------------------------
Questar Corp or Questor Corp
??????
-------------------------------------------------
RiboTargets
http://www.ribotargets.com/
Homepage for Vernalis
http://www.ribotargets.com/news/rib_prs/210303.htm
21 March 2003
Proposed Merger of British Biotech and RiboTargets
The boards of British Biotech and RiboTargets are pleased to announce
that they have agreed the terms of a Merger of the two companies to
create a Merged Group with a pro-forma market capitalisation of £52
million and Net Cash as at 28 February of £43.5 million, with a
further £7.9 million receivable from certain RiboTargets shareholders
upon completion of the Merger.
http://www.biotechanalytics.com/News/b/british_biotech.htm
1st October 2003 - British Biotech Plc - British Biotech plc AGM Update
British Biotech plc (today to be renamed Vernalis plc, subject to
shareholder approval) has been transformed during 2003 through two
substantial mergers, and the Company is continuing to achieve further
advances through important pipeline progress and extensive post-merger
restructuring.
The first merger with the privately-held company RiboTargets Holdings
plc was completed in April 2003 and brought a high quality,
structure-based drug discovery capability focused on novel cancer
targets. The second merger with Vernalis Group plc, completed in
September 2003, brought a marketed product, frovatriptan, a clinical
portfolio and innovative discovery programmes focused on central
nervous system disorders. The integration of British Biotech and
RiboTargets has been fully completed, and the integration of Vernalis
is progressing ahead of schedule.
http://www.ribotargets.com/corporate/overview.htm
http://www.vernalis.com/corporate/overview.htm
Vernalis is a new force in UK biotechnology formed out of the
September 2003 merger of British Biotech plc and Vernalis Group plc.
This merger has created a company with significant growth potential,
through sales of its marketed product, frovatriptan, the successful
development and commercialisation of its product pipeline candidates,
and through further participation in the consolidation of the UK
biotechnology sector.
-------------------------------------------------
Simulations Plus, Inc
http://www.simulations-plus.com/
Simulations Plus, inc.
Simulations Plus, Inc. is the leading developer of Absorption,
Distribution, Metabolism, Excretion and Toxicity (ADMET) neural net
and simulation software for the pharmaceutical and biotechnology
industries today. Its software allows pharmaceutical scientists to
predict certain key potential drug dynamics, such as absorption, in
silico, thereby eliminating multi-million dollar clinical trial
failures and speeding up the time to market of effective new
medications.
In addition, the Company's award-winning FutureLab science experiment
simulation software titles allow middle and high school students to
grasp various scientific concepts in an interactive, visually exciting
way.
Our wholly-owned subsidiary, Words+, Inc., produces computer software
and specialized hardware for use by persons with disabilities, as well
as a personal productivity software program called Abbreviate!
-------------------------------------------------
SPCSS, Inc.
Nothing with this name.
http://www.spss.com/
SPSS Inc.
SPSS has become a leader in predictive analytics technologies through
a combination of commitment to innovation and dedication to customers.
Throughout our history, we have produced predictive analytics software
that enables our customers ? corporations, academic institutions,
healthcare providers, and government agencies ? to better focus their
operations.
-------------------------------------------------
Structural Bioinformatics, Inc
http://www.bioscorpio.com/structural_bioinformatics_inc.htm
Structural Bioinformatics, Inc. (U. S.)
10929 Technology Place, San Diego, CA 92127
Tel.: 858-675-2400, Fax: 858-618-1041, WS: www.strubix.com
http://www.strubix.com/press_releases.html
Structural Bioinformatics and GeneFormatics Announce Merger
San Diego, CA, January 06, 2003?Structural Bioinformatics, Inc. (SBI)
and GeneFormatics, Inc. (GFI) announced today that they have agreed to
merge operations to create the new leader in proteomics-based drug
discovery. The merger has been approved by the two companies' boards
of directors and is subject to final approval from the California
Department of Corporations and the shareholders of both companies.
http://www.strubix.com/corporate_info.html
Cengent Therapeutics Inc.
Cengent Therapeutics is a structure-guided drug discovery company
utilizing integrated, proprietary computational and experimental lab
technologies to accelerate and optimize the drug discovery process.
Cengent was formed following the synergistic merger of Structural
Bioinformatics Inc. and GeneFormatics, both leaders in
structure-driven drug discovery. Cengent currently has four
pre-clinical programs in obesity/diabetes, anti-infectives, oncology,
and inflammation.
http://www.strubix.com/
Cengent Therapeutics Inc.
Cengent Therapeutics provides the most comprehensive suite of
structural services and capabilities for accelerating and optimizing
the drug discovery process. The company's technologies include: Genes
To Leads® to accelerate and validate lead discovery; Structure
Determination Services including augmented homology modeling, X-ray
crystallography, and nuclear magnetic resonance (NMR) spectroscopy;
StructureBank®, a database for the comparative analysis of protein
targets and anti-targets; Proteome Analysis, a suite of technologies
providing target identification and function information; and
BioprospectorTM for data-mining and pattern recognition.
-------------------------------------------------
Structural GenomiX
http://www.stromix.com/index.php
Structural GenomiX (SGX)
SGX is a leader in high-throughput structure determination and its
application to drug discovery. We intend to forge strategic alliances
and to market our target and protein family programs to the
pharmaceutical and biotechnology industries.
Currently, SGX's drug discovery programs include "designated target"
and drug discovery alliances, the 3D-IDTM program in anti-microbial
discovery, protein kinase programs, nuclear hormone receptor programs,
and a collaboration with the Cystic Fibrosis Foundation.
-------------------------------------------------
Trega Biosciences, Inc
http://www.trega.com links to a ?name available? page
http://www.bioscorpio.com/trega_biosciences_inc.htm
Trega Biosciences, Inc. (U. S.)
9880 Campus Point Dr., San Diego, CA 92121
Tel.: 619-410-6500, 619-455-2877, Fax: 619-410-6501, WS: www.trega.com
Public (NASDAQ: TRGA)
Acquired by LION bioscience AG (Germany) in March 2001
http://www.lionbioscience.com/press/release/2001/e9173/index_eng.html
LION bioscience Completes Acquisition of Trega Biosciences
HEIDELBERG, GERMANY, March 14, 2001 LION bioscience AG (Neuer Markt:
LIO, WKN: 504 350; Nasdaq: LEON) announced today that it has completed
the acquisition of 100% of the equity of Trega Biosciences, Inc. in
exchange for LION American Depository Shares (ADS) effective March 14,
2001.
-------------------------------------------------
Tripos, Inc
http://www.tripos.com/
Tripos
Tripos is a leading provider of discovery chemistry, integrated
discovery software products, software consulting services, and
discovery research services to the pharmaceutical, biotechnology,
agrochemical, and other life sciences industries. The company combines
information technology and scientific research to optimize and
accelerate molecular research for the discovery of new products by
customers.
-------------------------------------------------
Tularik Inc
http://www.tularik.com/home.php
Tularik Inc.
Our drug discovery approach, which is based on gene regulation, is
amenable to the development of orally available therapeutics or in
other words, pills. Such drugs are well suited for the treatment of
chronic diseases requiring daily administration of medications over
many years. Our strong understanding of gene regulatory pathways and
the efficiencies captured through our state-of-the-art integrated R&D
platform places us in a leading position to develop important new
medicines for the 21st century. |
